Search research articles
Contact Us
Filters
Showing results (901-910 of 922) with videos related to
Page
of 93
Sort By:
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Frontiers in Immunology
|
October 7, 2022
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
Daniel Leung, Xiaofeng Mu, Jaime S Rosa Duque, et al.
Leukemia
|
May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
Michael Grever, Leslie Andritsos, Versha Banerji, et al.
World Journal of Pediatrics : WJP
|
December 12, 2023
Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents
Jaime S Rosa Duque, Samuel M S Cheng, Carolyn A Cohen, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Leukemia & Lymphoma
|
September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemia
Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Blood Cancer Journal
|
December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Lancet (London, England)
|
March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Page
of 93
Search research articles
Search
Showing results (901-910 of 922) with videos related to
Sort By:
Page
of 93
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.
Frontiers in Immunology
|
October 7, 2022
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
Daniel Leung, Xiaofeng Mu, Jaime S Rosa Duque, et al.
Leukemia
|
May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
Michael Grever, Leslie Andritsos, Versha Banerji, et al.
World Journal of Pediatrics : WJP
|
December 12, 2023
Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents
Jaime S Rosa Duque, Samuel M S Cheng, Carolyn A Cohen, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Leukemia & Lymphoma
|
September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemia
Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Blood Cancer Journal
|
December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Lancet (London, England)
|
March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Page
of 93